PSNL

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Genetics, Health Technology, Oncology, Genomics, Cancer, Conference, PSNL

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.

Key Points: 

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Genomics, PSNL, Immunotherapy, Patient, NeXT, Abstract, AACR, MRD, Melanoma, Neoplasm, Medical imaging

“Personalis is excited to present data showing our ultra-sensitive MRD test, NeXT Personal, has the potential to find recurrent cancer earlier and monitor response in late-stage cancer patients receiving immunotherapy,” said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

Key Points: 
  • “Personalis is excited to present data showing our ultra-sensitive MRD test, NeXT Personal, has the potential to find recurrent cancer earlier and monitor response in late-stage cancer patients receiving immunotherapy,” said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.
  • Personalis will be sharing progress with collaborative research findings as well as the latest clinical results related to NeXT Personal.
  • Changes in ctDNA levels detected with NeXT Personal predicted therapy response and overall survival in late-stage hepatocellular carcinoma patients treated with a personalized cancer vaccine.
  • Analytical validation of NeXT Personal demonstrated ultra-sensitivity down to 1 PPM of ctDNA and high specificity, reinforcing the potential to detect recurrent cancer earlier.

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Genetics, Health, Oncology, WGS, Genomics, Plasma, Congress, PPM, PSNL, NSCLC, Adenocarcinoma, Patient, Publishing, DNA, Cancer, LUAD, Lung cancer, NeXT, Neoplasm, ESMO, MRD, Medicare, Recurrence, Medical imaging

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay.
  • “The robust validation results in this publication provide a foundational building block towards achieving Medicare coverage for NeXT Personal,” said Richard Chen, MD, MS, Chief Medical Officer and Executive Vice President, R&D of Personalis.
  • “Taken together, the results show NeXT Personal’s capability for ultra-sensitive detection of ctDNA in patient plasma samples and the test’s potential to reliably inform clinicians and patients on residual cancer, cancer treatment response, and cancer recurrence through ctDNA detection, earlier than conventional detection approaches,” Chen noted.
  • This data from the TRACERx Study demonstrated the assay was able to find cancer nearly a year ahead of imaging and was predictive of clinical outcomes in early-stage lung cancer patients.

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Technology, Genetics, Software, Pharmaceutical, Biotechnology, Genomics, Employment, Compensated emancipation, PSNL

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual’s entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Key Points: 
  • The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual’s entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The inducement stock options granted on November 15, 2023 have an exercise price of $1.11 per share, which is equal to the closing price of Personalis’ common stock on the grant date.
  • The inducement stock options granted on March 15, 2024 have an exercise price of $1.61 per share, which is equal to the closing price of Personalis’ common stock on the grant date.
  • The foregoing inducement awards are subject to the terms and conditions of Personalis’ 2020 Inducement Plan, and the terms and conditions of the applicable award agreement covering each grant.

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, PSNL, Neoplasm, Immunotherapy, Investment, DX, Lung, LDT, NeXT, Medicare, Tempus, MRD, Genomics, Partnership, Video game

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.
  • “Our efforts in 2024 continue to be focused on executing our Win-in-MRD strategy for NeXT Personal.
  • The conference call can be accessed live by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers.
  • A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 14, 2024
Oncology, Health, Technology, Genetics, Software, Pharmaceutical, Biotechnology, Interest, PSNL, Genomics, Cancer

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024.
  • In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
  • Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers.
  • The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com.

Personalis to Participate at Upcoming Investor Conferences

Retrieved on: 
Wednesday, January 31, 2024
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, PSNL, Cancer, Genomics

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences:

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences:
    Participating on Tuesday, February 13, 2024 at The Cliff Lodge in Snowbird, UT
    Presenting on Wednesday, March 6, 2024 at 12:50 p.m. Eastern Time at the Boston Marriott Copley Place in Boston, MA

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

Retrieved on: 
Tuesday, January 30, 2024
Technology, Medical Devices, Genetics, Health Technology, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Oncology, Partnership, Epigenomics, Biomarker, Patient, Drug resistance, Genomics, PSNL, Cancer, MRD

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health , Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health , Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform.
  • “Commercial partnerships such as this broaden our portfolio and are expected to appeal to a wide range of biopharma customers and accelerate our revenue growth.”
    Echoing this sentiment, Dave Mullarkey, CEO of ClearNote Health, remarked, “Partnering with Personalis presents an excellent opportunity to bring our 5hmC technology to the forefront of cancer research.
  • This alliance is a testament to the synergy between our two companies, enabling us to expand our reach and significantly impact the biopharmaceutical industry.
  • The partnership marks a pivotal moment in cancer research, leveraging the strengths of both companies to offer unparalleled solutions in the biopharmaceutical industry.

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, January 17, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Genetics, Genomics, Employment, PSNL, Compensated emancipation

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 29,000 shares of its common stock to eight new employees under Personalis’ 2020 Inducement Plan.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 29,000 shares of its common stock to eight new employees under Personalis’ 2020 Inducement Plan.
  • The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual’s entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Personalis is making this announcement as required by Nasdaq rules.
  • The foregoing inducement awards are subject to the terms and conditions of Personalis’ 2020 Inducement Plan, and the terms and conditions of the applicable award agreement covering each grant.

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

Retrieved on: 
Tuesday, January 16, 2024
Research, Medical Devices, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, MSI, LCD, Patient, Form 1095, PSNL, DNA, Medicare, RNA, DX, TMB, Genomics, NeXT, Transcriptome, Microsatellite instability, FDA, Biomarker, Palmetto, Clinical trial, Physician, Health insurance

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay , providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its NeXT Dx ultra-comprehensive tumor genomic profiling assay , providing access for the nation’s 66 million Medicare and Medicare Advantage beneficiaries.
  • Matching patients to their optimal cancer therapy requires a testing platform that can accurately report a broader range of clinically actionable genomic alterations.
  • Coverage for NeXT DX was extended effective August 29, 2023, under the Palmetto GBA MolDx program foundational Local Coverage Determination (LCD) L38119 (“Next-Generation Sequencing for Solid Tumors”).
  • Personalis estimates that approximately half of new solid tumor cancer cases will be diagnosed in patients covered by Medicare.